Reversible, extremely severe hypothyroidism in a patient with chronic hepatitis C treated with interferon-alpha

被引:0
|
作者
Sato, K
Miyakawa, M
Demura, H
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 55-year-old patient with chronic hepatitis C received interferon-alpha (IFN-alpha) therapy in March-August 1992. After a few months of treatment, easy fatigability, general malaise, nonpitting edema, and facial edema developed. After treatment for 22 weeks, the patient, with typical clinical features of myxedema, was referred to our outpatient clinic with undetectable serum levels of T-4 (<1.0 mu g/dL) and T-3 (<25 ng/dL) and a markedly elevated TSH level (217 mu U/mL). The serum thyroglobulin concentration was also undetectable (less than 5 ng/mL), suggesting that thyroid function was completely abolished. Following supplementation therapy with L-thyroxine, all the symptoms gradually disappeared. The patient remained euthyroid for nearly 2 years at a daily oral dose of 100 mu g L-thyroxine. To clarify whether the IFN-alpha-induced hypothyroidism was reversible, L-thyroxine was discontinued after obtaining informed consent. The patient thereafter remained in a euthyroid state, without any significant symptoms, for more than 11 months. The present case indicates that hypothyroidism induced by IFN-alpha treatment may be reversible, even if it has developed over a prolonged period and become severe, resulting in undetectable serum levels of T-3, T-4, and thyroglobulin.
引用
收藏
页码:249 / 252
页数:4
相关论文
共 50 条
  • [31] Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
    Teuber, G
    Berg, T
    Hoffmann, RM
    Leifeld, L
    Lafrenz, M
    Spengler, U
    Pape, GR
    Hopf, U
    Zeuzem, S
    DIGESTION, 2000, 61 (02) : 90 - 97
  • [32] INTERFERON-ALPHA IS EFFECTIVE IN THE TREATMENT OF CHRONIC HEPATITIS-C
    WORMAN, HJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1995, 90 (04): : 679 - 680
  • [33] Human leucocyte interferon-alpha in the treatment of chronic hepatitis C
    Mazzoran, L
    Zorat, F
    Chemello, L
    Crocè, LS
    Rigato, I
    Cavalletto, L
    Bernardinello, E
    Tiribelli, C
    Alberti, A
    Pozzato, G
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (04) : 347 - 352
  • [34] IRON AND RESPONSE TO INTERFERON-ALPHA IN CHRONIC HEPATITIS-C
    FARGION, S
    CARAZZONE, A
    MOLTENI, V
    BOLDORINI, R
    SAMPIETRO, M
    FRACANZANI, AL
    DALBA, R
    RONCHI, G
    PIPERNO, A
    FIORELLI, G
    HEPATOLOGY, 1995, 22 (04) : 1234 - 1234
  • [35] Treatment of children with chronic hepatitis C with recombinant interferon-alpha
    Lacaille, F
    Micali, N
    Lachaux, A
    Morali, A
    Sarles, J
    Rieu, D
    Chouraqui, JP
    Maurage, C
    Gottrand, F
    ARCHIVES DE PEDIATRIE, 2002, 9 (03): : 339 - 340
  • [36] Severe intraocular complications of interferon-alpha and ribavirin therapy in patients with chronic viral hepatitis C
    Sène, D
    Bodaghi, B
    Saadoun, D
    Touitou, V
    Perlemuter, G
    Cassoux, N
    Piette, JC
    Hoang, PL
    Cacoub, P
    HEPATOLOGY, 2004, 40 (04) : 330A - 330A
  • [37] Clonal T-cell expansions in interferon-alpha treated patients with chronic hepatitis C
    Heberer, B
    Heinemann, A
    Pingel, S
    Galle, P
    Loehr, H
    JOURNAL OF HEPATOLOGY, 2001, 34 : 142 - 143
  • [38] Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
    Alay, Handan
    Ozden, Kemalettin
    Erol, Serpil
    Celik, Neslihan
    Parlak, Emine
    Parlak, Mehmet
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2018, 24 (02): : 25 - 42
  • [39] IMPROVEMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS-C PATIENTS TREATED WITH NATURAL INTERFERON-ALPHA
    HIRAMATSU, N
    HAYASHI, N
    HAGIWARA, H
    TAKEHARA, T
    HARUNA, Y
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    HEPATOLOGY, 1992, 16 (04) : A205 - A205
  • [40] An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia
    Whiteway, AJ
    Reid, CDL
    Cross, NCP
    LEUKEMIA, 1997, 11 (04) : 614 - 616